Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.
The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.
Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.
In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.
The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.
Alnylam Pharmaceuticals has appointed Dr. Elliott Sigal to its Board of Directors, enhancing its leadership at a pivotal moment. With decades of experience, including his role as Chief Scientific Officer at Bristol-Myers Squibb, Dr. Sigal contributed to the launch of 14 new medicines across various therapeutic areas. His expertise is expected to strengthen Alnylam's ongoing efforts in advancing RNAi therapeutics aimed at rare diseases. The company continues its pursuit of transforming healthcare through innovative treatments, guided by its 'Alnylam P5x25' strategy.
Adaptimmune Therapeutics (ADAP) presented promising preclinical evidence for its next-gen SPEAR T-cells (ADP-A2M4N7X19) and engineered TILs (ADP-TILIL7) at the ASGCT annual meeting. The SPEAR T-cells are designed to enhance treatment durability and immune response in solid tumors by secreting IL-7 and CCL19. The company plans to initiate Phase 1 trials for both therapies targeting various solid tumors and metastatic melanoma, respectively. These advancements suggest improved potential for cancer treatment, building on results from Adaptimmune's earlier T-cell therapies.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported financial results for Q1 2022, highlighting a revenue increase to $3.6 million from $0.4 million year-over-year, attributed to heightened development activities. However, R&D expenses rose to $36.8 million from $24.5 million, and G&A expenses increased to $16.8 million compared to $13.8 million in Q1 2021. The net loss was $50.3 million, up from $37.8 million. The company remains funded into early 2024 and will present data on its therapies at upcoming conferences, including ASCO and ASGCT.
Adaptimmune Therapeutics (Nasdaq: ADAP) has appointed Dr. Joanna Brewer as Chief Scientific Officer (CSO) effective immediately. Dr. Brewer, who previously served as Senior Vice President of Allogeneic Research, has a robust background in cell therapy and has been instrumental in developing the company’s iPSC-derived T-cell therapies. This role aims to enhance Adaptimmune's scientific research and advance its pipeline of cancer immunotherapies, positioning the company for continued innovation in the treatment of various cancers.
Adaptimmune Therapeutics (Nasdaq: ADAP) will announce its financial results for Q1 2022 on May 9, 2022, before US market opening. The company specializes in cancer immunotherapy and utilizes its SPEAR® T-cell platform to develop innovative treatments. Following the earnings release, a live teleconference and webcast will be held at 8:00 a.m. EDT. Interested parties can access the webcast via the company’s investor website. The PR emphasizes the company's commitment to advancing its TCR therapeutic candidates, while cautioning about the inherent risks and uncertainties in clinical development.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) presented significant findings at the AACR annual meeting regarding its MAGE-A4-targeting SPEAR T-cell therapies. The data confirms MAGE-A4 as a viable target for multiple solid tumors, with a 67% eligibility rate in synovial sarcoma and 20%-35% across other cancers such as lung and bladder. Out of 6167 patients screened, 2729 were eligible, highlighting a robust patient pool for ongoing trials. These results build upon prior data, emphasizing Adaptimmune's commitment to advancing cancer treatment options.
Gennao Bio has appointed Peter Thompson, M.D., and Bradley Campbell to its Board of Directors. Peter Thompson brings extensive biotech experience in oncology and unmet medical needs, while Bradley Campbell has a strong background in orphan drug development. CEO Stephen Squinto expressed optimism about leveraging their expertise to advance Gennao's proprietary gene monoclonal antibody (GMAB) platform. The company aims to address significant needs in oncology and rare skeletal muscle diseases with its innovative, non-viral delivery system.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced major developments in cancer therapies, particularly targeting MAGE-A4. The SPEARHEAD-1 trial met its primary endpoint, paving the way for a BLA submission for afami-cel by Q4 2022. The company is advancing its allogeneic platform with an IND submission planned for 2023. Revenue for 2021 reached $6.1 million, a rise attributed to increased collaboration activities. However, R&D expenses rose to $111.1 million, contributing to a net loss of $158.1 million. The company confirmed financial guidance, projecting liquidity into early 2024.
Adaptimmune Therapeutics plc (Nasdaq:ADAP) will report its financial results for Q4 and the full year ending December 31, 2021, on March 14, 2022, before U.S. markets open. The announcement will be followed by a live teleconference and webcast at 8:30 a.m. EDT (12:30 p.m. GMT). The company focuses on developing cancer immunotherapy products using its SPEAR® T-cell platform to target multiple solid tumors. Investors can access the press release and webcast on the company's investor website.
Ensemble/Mosaic and Oxford Properties Group have formed a strategic partnership to develop up to 3 million square feet of life science properties at the Navy Yard in Philadelphia. This includes an investment in five existing properties and plans for two new buildings: 1201 Normandy Place (137,000 sq ft) and 333 Rouse Boulevard (105,000 sq ft), set to commence construction in 2022. Oxford's investment will enhance its $2 billion life science portfolio across North America, driven by a growing ecosystem of educational institutions and innovative companies.
FAQ
What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is Adaptimmune Therapeutics' primary focus?
What are the key programs of Adaptimmune Therapeutics?
What is afami-cel?
When is afami-cel expected to be commercially available?
What is lete-cel?
What are Adaptimmune’s recent strategic collaborations?
Where are Adaptimmune’s U.S. operations based?
What is Adaptimmune’s approach to cancer treatment?
What are the financial projections for Adaptimmune?
How can one get more information about Adaptimmune’s pipeline and operations?
